Beijing SL Pharmaceutical Co Ltd (002038) - Total Liabilities
Based on the latest financial reports, Beijing SL Pharmaceutical Co Ltd (002038) has total liabilities worth CN¥327.96 Million CNY (≈ $47.99 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Beijing SL Pharmaceutical Co Ltd (002038) cash conversion ratio to assess how effectively this company generates cash.
Beijing SL Pharmaceutical Co Ltd - Total Liabilities Trend (2001–2024)
This chart illustrates how Beijing SL Pharmaceutical Co Ltd's total liabilities have evolved over time, based on quarterly financial data. Check 002038 cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Beijing SL Pharmaceutical Co Ltd Competitors by Total Liabilities
The table below lists competitors of Beijing SL Pharmaceutical Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Biotest Aktiengesellschaft
XETRA:BIO
|
Germany | €906.90 Million |
|
Triveni Engineering & Industries Limited
NSE:TRIVENI
|
India | Rs15.63 Billion |
|
Qisda Corp
TW:2352
|
Taiwan | NT$142.09 Billion |
|
Brookline Bancorp Inc
NASDAQ:BRKL
|
USA | $10.31 Billion |
|
Longyan Zhuoyue New Energy Co Ltd
SHG:688196
|
China | CN¥781.60 Million |
|
Fujian Apex Software Co Ltd
SHG:603383
|
China | CN¥235.00 Million |
|
Everlight Chemical Industrial Corp
TW:1711
|
Taiwan | NT$4.36 Billion |
|
Heilongjiang ZBD Pharmaceutical Co Ltd
SHG:603567
|
China | CN¥4.51 Billion |
Liability Composition Analysis (2001–2024)
This chart breaks down Beijing SL Pharmaceutical Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see 002038 company net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 12.37 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.06 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.05 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Beijing SL Pharmaceutical Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Beijing SL Pharmaceutical Co Ltd (2001–2024)
The table below shows the annual total liabilities of Beijing SL Pharmaceutical Co Ltd from 2001 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥398.37 Million ≈ $58.29 Million |
-14.83% |
| 2023-12-31 | CN¥467.72 Million ≈ $68.44 Million |
+17.93% |
| 2022-12-31 | CN¥396.60 Million ≈ $58.04 Million |
-8.67% |
| 2021-12-31 | CN¥434.23 Million ≈ $63.54 Million |
+5.89% |
| 2020-12-31 | CN¥410.09 Million ≈ $60.01 Million |
+1.57% |
| 2019-12-31 | CN¥403.76 Million ≈ $59.08 Million |
-14.05% |
| 2018-12-31 | CN¥469.73 Million ≈ $68.74 Million |
+64.43% |
| 2017-12-31 | CN¥285.67 Million ≈ $41.80 Million |
+88.95% |
| 2016-12-31 | CN¥151.19 Million ≈ $22.12 Million |
+1.88% |
| 2015-12-31 | CN¥148.40 Million ≈ $21.72 Million |
+7.60% |
| 2014-12-31 | CN¥137.92 Million ≈ $20.18 Million |
+12.05% |
| 2013-12-31 | CN¥123.09 Million ≈ $18.01 Million |
+17.04% |
| 2012-12-31 | CN¥105.17 Million ≈ $15.39 Million |
+108.19% |
| 2011-12-31 | CN¥50.52 Million ≈ $7.39 Million |
+35.72% |
| 2010-12-31 | CN¥37.22 Million ≈ $5.45 Million |
+1.28% |
| 2009-12-31 | CN¥36.75 Million ≈ $5.38 Million |
+41.86% |
| 2008-12-31 | CN¥25.91 Million ≈ $3.79 Million |
-25.36% |
| 2007-12-31 | CN¥34.71 Million ≈ $5.08 Million |
-1.98% |
| 2006-12-31 | CN¥35.41 Million ≈ $5.18 Million |
+51.19% |
| 2005-12-31 | CN¥23.42 Million ≈ $3.43 Million |
-17.47% |
| 2004-12-31 | CN¥28.38 Million ≈ $4.15 Million |
-22.84% |
| 2003-12-31 | CN¥36.78 Million ≈ $5.38 Million |
+113.50% |
| 2002-12-31 | CN¥17.23 Million ≈ $2.52 Million |
+58.96% |
| 2001-12-31 | CN¥10.84 Million ≈ $1.59 Million |
-- |
About Beijing SL Pharmaceutical Co Ltd
Beijing SL Pharmaceutical Co., Ltd., a biopharmaceutical company, research, development, and production of genetic engineering and related drugs People's Republic of China and internationally. The company's finished formulations include temozolomide; arsenic trioxide; lenalidomide capsules; pegylated human granulocyte-stimulating factor injection; human granulocyte-cell stimulating factor injecti… Read more